LYNX DX

Lynx Dx is grounded in the foundational work conducted by research scientists at the University of Michigan who discovered that 75% of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG fuse together (T2:ERG), creating an "on switch" for prostate cancer development. The resulting screening test MyProstateScore (MPS) has provided patients with individualized, non-invasive risk assessments for prostate cancer by measuring urine levels of two unique cancer genes, T2:ERG and PCA3. MPS has proven to eliminate unnecessary biopsies for men who have elevated PSA results but do not have the two genetic markers present... Lynx Dx provides best-in-class diagnostic testing services to help people live healthy and productive lives.

Primary location: Ann Arbor United States